"Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)." by Jacob Drobnyk Soumerai

Selected Works of John M. Pagel, MD, PhD

Article

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Journal of Clinical Oncology (2018)

Jacob Drobnyk Soumerai, Harvard University
John M. Pagel, Swedish Cancer Institute, Seattle, WA;
Deepa Jagadeesh, Cleveland Clinic
Huda S. Salman, Stony Brook University
Vaishalee Padgaonkar Kenkre, University of Wisconsin-Madison
Adam Steven Asch, University of Oklahoma
Anastasios Stathis, IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;
Nishitha M. Reddy, Vanderbilt University
Alexia Iasonos, Memorial Sloan Kettering Cancer Center
Richard Ghalie, MEI Pharma, Inc., San Diego, CA;
Andrew David Zelenetz, Memorial Sloan Kettering Cancer Center

Link

Disciplines

Publication Date

May 20, 2018

DOI

10.1200/jco.2018.36.15_suppl.7519

Citation Information

Jacob Drobnyk Soumerai, John M. Pagel, Deepa Jagadeesh, Huda S. Salman, et al.. "Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)." Journal of Clinical Oncology Vol. 36 (2018) p. 7519 - 7519
Available at: http://works.bepress.com/john-pagel/296/